Navigation Links
PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
Date:1/9/2008

BOSTON, Jan. 9 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services organization, today announced that Eduard E. Holdener, M.D., formerly Head of Global Pharmaceutical Development at F. Hoffmann-La Roche, Ltd., has been elected to its Board of Directors.

Dr. Holdener was recently appointed to the role of non-executive Chairman of NovImmune. The biotechnology Company develops new therapeutic agents in the field of immune-related disorders and inflammation.

"With 22 years of biopharmaceutical industry experience, which has included managing global operations and overseeing global drug development during the past nine years for a major pharmaceutical company, Dr. Holdener will be an excellent addition to PAREXEL and our Board of Directors," said Josef von Rickenbach, PAREXEL's Chairman and Chief Executive Officer. "Our clients and shareholders will certainly benefit from the extensive expertise Dr. Holdener brings to the Company as we continue to be a premier provider to the biopharmaceutical industry in the development and commercialization of important new therapies worldwide."

In his former role as Global Head of Pharmaceutical Drug Development at Roche, Dr. Holdener successfully led a worldwide development organization, which was instrumental in receiving approvals for key oncology, virology, rheumatology, and anemia drugs in many related indications. He also served as the Company's Chief Medical Officer. During his career with the Company, he helped to establish and expand the oncology therapeutic area, and was presented with the Roche Research and Development Prize in the early 90's. Dr. Holdener led the Company's development operations in Japan for several years in the late 90's, and was instrumental during the Roche/Chugai merger at the beginning of this millennium. He was also responsible for establishing a new development center in Shanghai, China in 2007. Dr. Holdener served on several executive committees at the departmental, divisional, and corporate levels, which focused particularly on portfolio strategies and functional excellence. Prior to joining Roche, Dr. Holdener held positions as a clinical oncologist in hospital settings and academic institutions, both in Switzerland and the United States.

Dr. Holdener received his Medical Degree from the University of Zurich and Basel Medical School in Switzerland, and completed his fellowship in Oncology at the University of Kansas Medical Center in the United States. He is Board Certified in Internal Medicine and Oncology/Hematology in Switzerland.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has approximately 7,000 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contact for investors and analysts:

Jill Baker

Vice President, Investor Relations

Tel: 781-434-4118

Email: Jill.Baker@PAREXEL.com

Contact for media:

Jennifer Baird

Director of Public Relations

Tel: 781-434-4409

Email: Jennifer.Baird@PAREXEL.com


'/>"/>
SOURCE PAREXEL
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
2. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
3. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
4. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
5. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
6. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
7. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
8. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
9. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
10. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
(Date:2/15/2017)... WARRINGTON, Pa. , Feb. 15, 2017 ... biotechnology company focused on developing aerosolized KL4 surfactant therapies ... webcast (including a slide presentation) at 8:00 AM EST ... the AEROSURF phase 2 clinical program, the recently announced ... business and development activities. To participate in ...
(Date:2/15/2017)... ... February 15, 2017 , ... ... a strategic partnership that puts Diameter Health technology in the hands of Lantana ... allows providers, exchanges, quality improvement and public health entities – all those mining ...
(Date:2/15/2017)... Feb. 15, 2017  Theravance Biopharma, Inc. (NASDAQ: ... announced that it will release financial results for the ... Monday, February 27, 2017. An accompanying ... on February 27, 2017. To participate in the live ... U.S., or (920) 663-6266 for international callers, using the ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... report to their offering. ... The global voice recognition biometrics market to grow ... The report covers the present scenario and the growth prospects ... the market size, the report considers the revenue generated from the ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
Breaking Biology News(10 mins):